▎WuXiEdited by the Kangde Content Team
BioNTech and MediLink Expand Collaboration on Antibody-Drug Conjugates
MediLink, formerly known as "Yilian Bio," recently announced a new strategic partnership with BioNTech. Based on this collaboration,BioNTech will obtain the exclusive option and corresponding global exclusive license to develop ADC products targeting specified cutting-edge innovative targets using MediLink's TMALIN antibody-drug conjugate (ADC) technology platform.
According to the terms of the new agreement, MediLink will receive an upfront payment of $25 million and is eligible to receive up to $1.8 billion in development, regulatory, and commercialization milestone payments. As part of the agreement, MediLink will have the right of first refusal for future collaboration if BioNTech seeks to out-license or transfer these ADC products in any one or more regional markets within Greater China.In October 2023, MediLink and BioNTech reached a strategic cooperation and global licensing agreement for YL202/BNT326, an ADC project targeting HER3. Both parties decided to further expand the scope of cooperation and reached this platform cooperation licensing agreement.Johnson & Johnson Acquires Potential "First-in-Class" Bispecific Antibody Therapy for Atopic DermatitisJohnson & Johnson announced today that it has reached a definitive agreement with Numab Therapeutics to acquire global development rights for the potential "first-in-class" bispecific antibody NM26 for approximately $1.25 billion.
NM26 is ready to enter Phase 2 clinical research. It targets two clinically validated signaling pathways in atopic dermatitis: the IL-4Rα subunit and IL-31. Atopic dermatitis is one of the most common inflammatory skin diseases, characterized by high heterogeneity, with different patient subgroups having different pathogenic mechanisms.NM26 targets IL-4Rα to triggerType 2 Helper T Cells (Th2)Mediated skin inflammation. It simultaneously targets IL-31 and IL-31-mediated skin itching, leading to subsequent scratching that exacerbates the condition.In addition to potentially changing the standard treatment for atopic dermatitis, NM26 may also be effective in other inflammatory skin conditions involving Th2 and pruritus.Exploring New Targets for Triple-Negative Breast Cancer and Non-Small Cell Lung Cancer, Gilead Sciences Announces CollaborationCartography Biosciences Announces Strategic Collaboration with Gilead Sciences to Discover and Develop Therapies for Triple-Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
In this multi-year collaboration, Cartography's proprietary computational and gene platforms will be used to discover and validate innovative tumor-selective target antigens.Cartography's ATLAS and SUMMIT platforms integrate single-cell data from comprehensive health controls and tumor atlases, applying target identification algorithms to identify individual antigens or antigen pairs specific to target cells.Gilead can choose multiple targets identified through this collaboration and assume all subsequent research, development, and commercialization work for these targets. Under the terms of the agreement, Cartography will receive a $20 million upfront payment as well as additional near-term preclinical milestone payments. Cartography is also eligible to receive development, regulatory, and commercial milestone payments.
▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.
References:
[1] Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis. Retrieved May 28, 2024, from https://www.businesswire.com/news/home/20240528509212/en
[2] Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs. Retrieved May 28, 2024, from https://www.businesswire.com/news/home/20240527063643/en/Cartography-Announces-Strategic-Collaboration-with-Gilead-to-Develop-Oncology-Therapies-Against-Novel-Targets-and-Target-Pairs
[3] MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech. Retrieved May 28, 2024, from https://www.medilinkthera.com/news-details/35
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.
Share，PointLike，In ViewFocusing on Global Biomedical Health Innovation
